HomeCompareAIABF vs JNJ

AIABF vs JNJ: Dividend Comparison 2026

AIABF yields 1538.46% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AIABF wins by $883991768.08M in total portfolio value
10 years
AIABF
AIABF
● Live price
1538.46%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$883991768.11M
Annual income
$783,774,560,703,885.50
Full AIABF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AIABF vs JNJ

📍 AIABF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIABFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIABF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIABF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIABF
Annual income on $10K today (after 15% tax)
$130,769.23/yr
After 10yr DRIP, annual income (after tax)
$666,208,376,598,302.60/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AIABF beats the other by $666,208,376,594,316.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIABF + JNJ for your $10,000?

AIABF: 50%JNJ: 50%
100% JNJ50/50100% AIABF
Portfolio after 10yr
$441995884.07M
Annual income
$391,887,280,354,287.44/yr
Blended yield
88.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AIABF
No analyst data
Altman Z
-0.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIABF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIABFJNJ
Forward yield1538.46%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$883991768.11M$30.3K
Annual income after 10y$783,774,560,703,885.50$4,689.40
Total dividends collected$876714122.30M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AIABF vs JNJ ($10,000, DRIP)

YearAIABF PortfolioAIABF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$164,546$153,846.15$10,592$272.30+$154.0KAIABF
2$2,541,933$2,365,868.50$11,289$357.73+$2.53MAIABF
3$36,877,139$34,157,271.11$12,123$472.89+$36.87MAIABF
4$502,577,470$463,118,930.88$13,141$629.86+$502.56MAIABF
5$6,436,433,977$5,898,676,084.35$14,408$846.81+$6436.42MAIABF
6$77,488,345,446$70,601,361,090.44$16,021$1,151.60+$77488.33MAIABF
7$877,278,013,079$794,365,483,451.57$18,122$1,588.22+$877277.99MAIABF
8$9,343,682,184,854$8,404,994,710,859.21$20,930$2,228.20+$9343682.16MAIABF
9$93,660,941,503,130$83,663,201,565,336.92$24,792$3,191.91+$93660941.48MAIABF
10$883,991,768,112,235$783,774,560,703,885.50$30,274$4,689.40+$883991768.08MAIABF

AIABF vs JNJ: Complete Analysis 2026

AIABFStock

Capital A Berhad, an investment holding company, provides air transportation services in Malaysia, Indonesia, the Philippines, and internationally under the AirAsia brand. It also offers management, engineering, tour operating, aircraft leasing, shared and outsourcing, central depository, financial and other related, event ticketing, and consultancy services, as well as services in the areas of information technology design, development, and implementation; facilitates business transactions for AirAsia Group with non-resident goods and service providers; and trades in coffee and tea related products, and multimedia content and equipment. In addition, the company provides inflight meal products; manages customer loyalty points; wholesales meat, fish, fruits, vegetables, flowers, and plants; offers online retail sales, inflight magazine content, inflight shop, aviation and commercial, airport related, food and beverages, and research and development services, as well as supporting services to air transport; and operates AirAsia Superapp. Further, it is involved in the marketing and development of loyalty programs; development of software for cybersecurity; and provision of media content, e-hailing, online food ordering, delivery, investment management, and cargo services, as well as provides logistic and payment services for cross border e-commerce marketing. The company was formerly known as AirAsia Group Berhad and changed its name to Capital A Berhad in January 2022. Capital A Berhad was founded in 2001 and is headquartered in Kuala Lumpur, Malaysia.

Full AIABF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AIABF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIABF vs SCHDAIABF vs JEPIAIABF vs OAIABF vs KOAIABF vs MAINAIABF vs ABBVAIABF vs MRKAIABF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.